Sequence Alterations in the Carboxyl- Terminal Propeptide Do main - Osteogenesis Imperfecta - page 124

[10] Lees JF, Tasab M, Bulleid NJ. Identiication of the molecular rec-

ognition sequence which determines the type-speciic assembly
of procollagen. EMBO J 1997;16(5):908-16.

[29] Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in

health and disease. Hum Mol Genet 1999;8(10):1893-900.

[30] Willing MC, Deschenes SP, Slayton RL, Roberts EJ. Premature

chain termination is a unifying mechanism for COL1A1 null
alleles in osteogenesis imperfecta type I cell strains. Am J Hum
Genet 1996;59(4):799-809.

[11] Doege KJ, Fessler JH. Folding of carboxyl domain and assembly

of procollagen I. J Biol Chem 1986;261(19):8924-35.

[12] Schoield JD, Uitto J, Prockop DJ. Formation of interchain disul-

ide bonds and helical structure during biosynthesis of procolla-
gen by embryonic tendon cells. Biochemistry 1974;13(9):1801-6.

[31] Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogen-

esis imperfecta mutations in the helical domain of type I collagen:
regions rich in lethal mutations align with collagen binding sites
for integrins and proteoglycans. Hum Mutat 2007;28(3):209-21.

[13] Olsen BR, Hoffmann H, Prockop DJ. Interchain disulide bonds

at the COOH-terminal end of procollagen synthesized by
matrix-free cells from chick embryonic tendon and cartilage.
Arch Biochem Biophys 1976;175(1):341-50.

[32] Forlino A, Cabral WA, Barnes AM, Marini JC. New per-

spectives on osteogenesis imperfecta. Nat Rev Endocrinol
2011;7(9):540-57. [14] Marini JC, Cabral WA, Barnes AM, Chang W. Components of

the collagen prolyl 3-hydroxylation complex are crucial for nor-
mal bone development. Cell Cycle 2007;6(14):1675-81.

[33] Vogel BE, Doelz R, Kadler KE, Hojima Y, Engel J, Prockop DJ.

A substitution of cysteine for glycine 748 of the alpha 1 chain
produces a kink at this site in the procollagen I molecule and an
altered N-proteinase cleavage site over 225 nm away. J Biol Chem
1988;263(35):19249-55.

[15] Nishikawa Y, Takahara Y, Asada S, et al. A structure-activity

relationship study elucidating the mechanism of sequence-
speciic collagen recognition by the chaperone HSP47. Bioorg
Med Chem 2010;18(11):3767-75. [34] Forlino A, Keene DR, Schmidt K, Marini JC. An alpha2(I) gly-

cine to aspartate substitution is responsible for the presence of
a kink in type I collagen in a lethal case of osteogenesis imper-
fecta. Matrix Biol 1998;17(8-9):575-84.

[16] Chessler SD, Byers PH. BiP binds type I procollagen pro alpha

chains with mutations in the carboxyl-terminal propeptide syn-
thesized by cells from patients with osteogenesis imperfecta.
J Biol Chem 1993;268(24):18226-33. [35] Vogel BE, Minor RR, Freund M, Prockop DJ. A point mutation

in a type I procollagen gene converts glycine 748 of the alpha 1
chain to cysteine and destabilizes the triple helix in a lethal vari-
ant of osteogenesis imperfecta. J Biol Chem 1987;262(30):14737-44.

[17] Lamande SR, Chessler SD, Golub SB, et al. Endoplasmic reticu-

lum-mediated quality control of type I collagen production by
cells from osteogenesis imperfecta patients with mutations in
the pro alpha 1 (I) chain carboxyl-terminal propeptide which
impair subunit assembly. J Biol Chem 1995;270(15):8642-9.

[36] Yang W, Battineni ML, Brodsky B. Amino acid sequence envi-

ronment modulates the disruption by osteogenesis imperfecta
glycine substitutions in collagen-like peptides. Biochemistry
1997;36(23):6930-5.

[18] Bachinger HP, Bruckner P, Timpl R, Prockop DJ, Engel J. Folding

mechanism of the triple helix in type-III collagen and type-III
pN-collagen. Role of disulide bridges and peptide bond isom-
erization. Eur J Biochem 1980;106(2):619-32.

[37] Dalgleish R. The human type I collagen mutation database.

Nucleic Acids Res 1997;25(1):181-7.

[19] Bachinger HP, Fessler LI, Timpl R, Fessler JH. Chain assembly

intermediate in the biosynthesis of type III procollagen in chick
embryo blood vessels. J Biol Chem 1981;256(24):13193-9.

[38] Dalgleish R. The human collagen mutation database 1998.

Nucleic Acids Res 1998;26(1):253-5.

[39] Cundy T, King A, Byers PH. A novel disorder of type I collagen

characterized by high bone mass, mineralization defect and ten-
don calciication. Calcif Tissue Int 2008:82S1.

[20] Kadler KE, Holmes DF, Trotter JA, Chapman JA. Collagen ibril

formation. Biochem J 1996;316( Pt 1 ):1-11.

[21] Prockop DJ, Hulmes DJ. Assembly of procollagen ibrils de novo

from soluble precursors Yurchenco PD, Birk DE, Mecham RP,
editors. Extracellular matrix assembly and structure. San Diego:
Academic Press; 1994. p. 47-90.

[40] Ries-Levavi L, Ish-Shalom T, Frydman M, et al. Genetic and bio-

chemical analyses of Israeli osteogenesis imperfecta patients.
Hum Mutat 2004;23(4):399-400.

[41] Lindahl K, Barnes AM, Fratzl-Zelman N, et al. COL1

C-propeptide cleavage site mutations cause high bone mass
osteogenesis imperfecta. Hum Mutat 2011;32(6):598-609.

[22] Colige A, Li SW, Sieron AL, Nusgens BV, Prockop DJ, Lapiere CM.

cDNA cloning and expression of bovine procollagen I N-proteinase:
a new member of the superfamily of zinc-metalloproteinases with
binding sites for cells and other matrix components. Proc Natl Acad
Sci USA 1997;94(6):2374-9.

[42] Pollitt R, McMahon R, Nunn J, et al. Mutation analysis of

COL1A1 and COL1A2 in patients diagnosed with osteogenesis
imperfecta type I-IV. Hum Mutat 2006;27(7):716.

[23] Colige A, Sieron AL, Li SW, et al. Human Ehlers-Danlos syn-

drome type VII C and bovine dermatosparaxis are caused by
mutations in the procollagen I N-proteinase gene. Am J Hum
Genet 1999;65(2):308-17.

[43] Perlmutter DH. Chemical chaperones: a pharmacological strat-

egy for disorders of protein folding and traficking. Pediatr Res
2002;52(6):832-6.

[44] Symoens S, Nuytinck L, Legius E, Malfait F, Coucke PJ, De

Paepe A. Met>Val substitution in a highly conserved region of
the pro-alpha1(I) collagen C-propeptide domain causes alter-
native splicing and a mild EDS/OI phenotype. J Med Genet
2004;41(7):e96.

[24] Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS.

Bone morphogenetic protein-1: the type I procollagen C-proteinase.
Science 1996;271(5247):360-2.

[25] Hopkins DR, Keles S, Greenspan DS. The bone morphoge-

netic protein 1/Tolloid-like metalloproteinases. Matrix Biol
2007;26(7):508-23.

[45] Chessler SD, Wallis GA, Byers PH. Mutations in the carboxyl-

terminal propeptide of the pro alpha 1(I) chain of type I collagen
result in defective chain association and produce lethal osteo-
genesis imperfecta. J Biol Chem 1993;268(24):18218-25.

[26] Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV, Prockop DJ.

The C-proteinase that processes procollagens to ibrillar colla-
gens is identical to the protein previously identiied as bone mor-
phogenic protein-1. Proc Natl Acad Sci USA 1996;93(10):5127-30.

[46] Pyott SM, Pepin MG, Schwarze U, Yang K, Smith G, Byers PH.

Recurrence of perinatal lethal osteogenesis imperfecta in sib-
ships: parsing the risk between parental mosaicism for domi-
nant mutations and autosomal recessive inheritance. Genet Med
2011;13(2):125-30.

[27] Moali C, Font B, Ruggiero F, et al. Substrate-speciic modula-

tion of a multisubstrate proteinase. C-terminal processing of
ibrillar procollagens is the only BMP-1-dependent activity to be
enhanced by PCPE-1. J Biol Chem 2005;280(25):24188-94. [47] Pace JM, Atkinson M, Willing MC, Wallis G, Byers PH.

Deletions and duplications of Gly-Xaa-Yaa triplet repeats in the
triple helical domains of type I collagen chains disrupt helix

[28] Canty EG, Kadler KE. Procollagen traficking, processing and

ibrillogenesis. J Cell Sci 2005;118(Pt 7):1341-53.